A test for serum glutamate, a naturally occurring amino acid in the blood, could be a new and less-invasive way to measure the aggressiveness of prostate cancer, according to new research from Roswell Park Cancer Institute (RPCI).
In two separate papers published in The Lancet Oncology, researchers have found two gene signatures, or "bar codes," that can predict how severe and aggressive prostate cancer could become, potentially improving accuracy of diagnosis and prognosis and supporting treatment decisions. They could potentially be used alongside the existing prostate-specific antigen test.
Genetic markers found by New York City researchers that could flag patients most at risk of erectile dysfunction after radiotherapy for prostate cancer may help doctors pick the best treatment for their patients.
MRI screening may be quite useful in managing prostate cancer patients and preventing overtreatment in the process.
CureVac, a biotech company pushing therapeutic cancer vaccines into Phase IIb studies, landed a cool $104 million from German multibillionaire Dietmar Hopp's investment group, dievini Hopp BioTech Holding.
Researchers from the University of Texas are heralding a childhood virus that causes respiratory infections in infants and young children as a targeted cancer treatment.
By finding a link between prostate cancer and the IL-16 gene in African American men, researchers have confirmed another potential marker for this.
Recent research published in The Journal of Urology suggests that combining drug treatment with the PSA biomarker could raise screening accuracy, particularly in men with hard to diagnose disease whose cancer might otherwise be missed.
Levels of a gene that helps the prostate to develop in the growing embryo could be used as a biomarker in prostate cancer, according to research carried out at the University of Edinburgh (U.K.), and sponsored by the charity Prostate Cancer UK.
The diagnosis of prostate cancer can involve repeat biopsies, particularly in men who have had a negative result. A genetic test developed at Wake Forest University School of Medicine could cut the need for these unpleasant and invasive repeat tests, reducing pain, anxiety and inconvenience for patients and cutting the risk of infection, as well as freeing time and budgets for healthcare providers.